Illumina to Acquire SomaLogic

Illumina, Inc. (NASDAQ: ILMN) announces it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. “The acquisition of SomaLogic will enhance Illumina’s presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future,” said Jacob Thaysen, chief executive officer of Illumina.

Read the full article: Illumina to Acquire SomaLogic //

Source: https://www.prnewswire.com/news-releases/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy-302488151.html

Scroll to Top